Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses challenges patients with multiple myeloma have faced as a result of the COVID-19 pandemic and the research he and his international colleagues are conducting to better understand these difficulties and improve patient care.
At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?
Recorded April 24, 2020.
William Dale, MD, PhD, of City of Hope National Medical Center, discusses vulnerable populations—older adults and those with psychosocial or mental health concerns—and reviews best practices for treatment decisions, social distancing, and maintaining emotional health. Recorded April 15, 2020.
Joseph C. Alvarnas, MD, of the City of Hope National Medical Center, discusses the patients with cancer who are at an increased risk for developing serious complications from COVID-19, including those receiving bone marrow or stem cell transplants and CAR-T cell therapy, and what they can do to protect themselves. Filmed April 17, 2020.
Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma?
Recorded April 24, 2020.
